Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
Genelux Corporation (GNLX)
Company Research
Source: GlobeNewswire
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across all dose cohorts; observed durable response signals and treatment tolerability (Phase 1b/2 SCLC) -- -- In advanced or metastatic recurrent NSCLC, observed anti-tumor activity in initial dose cohort and Olvi-Vec generally well tolerated (Phase 2 VIRO-25) -- -- Additional systemic lung cancer data expected throughout 2026, alongside topline data from Phase 3 ovarian cancer trial (OnPrime/GOG-3076) in second half of 2026 -- WESTLAKE VILLAGE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX)
Show less
Read more
Impact Snapshot
Event Time:
GNLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNLX alerts
High impacting Genelux Corporation news events
Weekly update
A roundup of the hottest topics
GNLX
News
- Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan PartnersGlobeNewswire
- Genelux (NASDAQ:GNLX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GNLX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common StockGlobeNewswire
- Genelux Corporation Announces Proposed Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Genelux Corporation Announces Proposed Public Offering of Common StockGlobeNewswire
GNLX
Sec Filings
- 1/8/26 - Form 8-K
- 1/8/26 - Form 424B5
- 1/7/26 - Form 4
- GNLX's page on the SEC website